Prevention of Gastrointestinal Toxicity From Total Body Irradiation or High Dose Chemotherapy With Pasireotide
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Pasireotide (Primary) ; Busulfan; Methotrexate
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 07 Nov 2019 Status changed from active, no longer recruiting to completed.
- 13 Mar 2019 Planned primary completion date changed from 4 Feb 2019 to 4 May 2019.
- 22 Jan 2019 Planned End Date changed from 1 Jan 2020 to 1 Oct 2019.